

In re: Michael Martin
Appl No.: 10/598,671
Filed: Sept. 7, 2006
Page 5

RECEIVED
CENTRAL FAX CENTER
NOV 22 2010

REMARKS/ARGUMENTS

The Applicant would like to thank the Examiner for the telephonic interview of October 27, 2010. The claims were discussed with regard to amending to identify specific therapies that would be amenable to targeting the Gsk-3 response. Specific treatment options discussed included septicemia treatments. No agreement on any claims was reached.

Claim amendments

Applicant has cancelled claims 1-29. Applicant adds new claims 30-50. The claims find support in the specification. Specifically, independent claims 30, 37, and 43 find support in Figure 4; page 2, paragraph [0012]; page 4, paragraph [0045]; page 6, paragraph [0066]; and Example 5. Dependant claims 31, 32, 38, 39, 44, and 45 find support on pages 12-13, paragraphs [0121-0122]. Dependant claims 33, 40, 46, and 50 find support on page 10, paragraph [0098]. Dependant claims 34 and 35 find support on page 6, paragraph [0062]. Dependant claims 36, 41, 42 find support on page 7, paragraph [0082]. Dependant claims 47, 48, and 49 find support on page 6, paragraphs [0063-0065], respectively.

Claim rejections under 35 U.S.C. § 102(b).

Applicant has cancelled claims 1-29, thereby obviating the rejection. New claims 30-50 are presented. The new independent claims are now directed to treating septicemia in its various forms, e.g., endotoxic shock, surgical septicemia, and other septic infections, respectively. The breakthrough discovery of Gsk-3 being involved in toxic responses to microorganisms allows for new treatments for infections by Gsk-3 inhibitors such as lithium. Such treatments were unknown and unexpected since Gsk-3 was only known previously as metabolic enzyme, not an immune modulator. Therefore, by disclosure of the mechanism, it is now possible to specifically target patients for treatment independent of antimicrobial agents, steroids, and non-steroidal anti-inflammatory drugs. Such therapies can even be combined to potentiate responses in patients.

In re: Michael Martin
Appl No.: 10/598,671
Filed: Sept. 7, 2006
Page 6

RECEIVED
CENTRAL FAX CENTER
NOV 22 2010

Should the Examiner have further questions or comments with respect to examination of this case, it is respectfully requested that the Examiner telephone the undersigned attorney so that further examination of this application can be expedited.

It is not believed that extensions of time or fees are required, beyond those which may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration, such extensions are hereby petitioned under 37 CFR § 1.136(a).

Respectfully submitted,



C. Allen Black, Esq.
Registration No. 53,835

THE LAW OFFICE OF C. ALLEN BLACK, PH.D.
1579 Montgomery Rd.
Allison Park, PA 15101
Tel Office (412) 908-3268
Fax Office (412) 318-4815

MM01/20674-0008US1

PAGE 8/8 * RCVD AT 11/22/2010 9:31:27 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/46 * DNIS:2738300 * CSID:412 318 4815 * DURATION (mm:ss):03:54